Catalent flags problems at its manufacturing plants; CFO departs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq hits record high after softer jobs data cuts rate-hike bets
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
Nephron Double Upgrades Catalent (CTLT) to Buy, 'The Best Activist Candidate'
April 14, 2023 10:37 AM EDTNephron analyst Jack Meehan upgraded Catalent (NYSE: CTLT) from Sell to Buy.
"The Best Activist Candidate in Life Sciences"For an analyst ratings summary and ratings history on Catalent click here. For more ratings news on Catalent click here.
Shares of Catalent closed at $63.31 yesterday.
... More